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Gram-negative bacteraemia is suspected, and
particularly for patients with neutropenia, haem-
atological malignancy or solid tumour, or who
have recently received antibiotics.
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ABSTRACT
This study evaluated the pharmacodynamics of
continuous infusion b-lactams against pulmonary
isolates of Gram-negative bacteria from patients
managed in intensive care units (ICUs) in the
USA. Multiple 10 000-patient Monte Carlo simu-
lations were performed by integrating pharmaco-
kinetic data from healthy individuals with 2408
MICs from the 2002 Intensive Care Unit Surveil-
lance System database. These pharmacodynamic
simulations suggested that continuous infusion
regimens of cefepime, aztreonam, ceftazidime
and piperacillin–tazobactam 13.5 g have the
greatest likelihood of achieving pharmacodynam-
ic targets against isolates of Enterobacteriaceae in
the ICU. b-Lactams are unlikely to achieve phar-
macodynamic targets against Pseudomonas aerugi-
nosa or Acinetobacter baumannii when adminis-
tered as monotherapy.
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The threat of antibiotic resistance, coupled with a
lack of new antibiotics active against Gram-
negative bacteria in the industrial pipeline, neces-
sitates more effective use of existing therapies.
b-Lactams are one of the most diverse and
clinically useful antibiotic classes, and are active
against a wide array of bacterial species in vitro
[1]. Unfortunately, in-vitro activity alone is not
sufﬁcient to ensure clinical success [2]. Clinical
effectiveness depends on the interplay between
in-vitro activity, pharmacokinetics, host immune
status, tolerability and patient compliance.
In the absence of clinical trial data, pharmaco-
dynamic models satisfy a critical need by
enabling the scientiﬁc community to predict the
likelihood of clinical success based on mathe-
matical models that integrate antimicrobial
susceptibility patterns and antimicrobial pharma-
cokinetics. Animal studies have demonstrated
previously that clinical success is best predicted
by one of three pharmacodynamic indices: the
percentage of time for which the concentration
remains above the MIC (%T > MIC); the ratio of
peak concentration to MIC (Cmax ⁄MIC); and the
ratio of area under the concentration–time curve
to MIC (AUC ⁄MIC) [1]. It has been demonstrated
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previously for b-lactams that animal survival
correlates best with %T > MIC [3,4]. This revela-
tion has prompted clinicians to develop dosing
strategies that maximise the%T > MIC, including
higher doses and shorter dosing intervals [5,6].
While these efforts are noteworthy, intermittent
b-lactam administration results in undesirable
high peak concentrations and low, potentially
sub-MIC, trough concentrations. Administering
b-lactams by continuous infusion avoids these
ﬂuctuations and enables the%T > MIC to remain
above 100% for the entire duration of treatment.
When b-lactams are administered by continuous
infusion, it can be hypothesised that optimal
bactericidal killing is achieved when the steady-
state concentration to MIC ratio (Css ⁄MIC) is ‡ 4
[7,8].
The present study evaluated the pharmacody-
namics of several b-lactams when administered
by continuous infusion against pulmonary iso-
lates of Gram-negative bacteria from patients
managed in intensive care units (ICUs) in the
USA, with the aim of providing valuable insights
into which continuous infusion b-lactam regi-
mens are most likely to treat Gram-negative
pulmonary infections in the ICU effectively.
The Intensive Care Unit Surveillance System
(ISS) database (Merck & Co., Rathway, NJ, USA)
has been described previously [9]. In short, the ISS
database is a multi-year, national survey of ICUs
in the USA. For the purpose of the present
analysis, only MIC data for pulmonary isolates
collected during 2002 were evaluated. Bacteria
were subdivided into three groups (Enterobacte-
riaceae, Acinetobacter baumannii and Pseudomonas
aeruginosa), and MIC frequency distributions were
created for each bacterium ⁄b-lactam combination.
In total, nine continuous infusion b-lactam
regimens were modelled, including piperacillin–
tazobactam 6.75 g and 13.5 g, piperacillin 6 g and
12 g, ceftazidime 2 g and 3 g, cefepime 3 g and
4 g, and aztreonam 6 g. Pharmacokinetic param-
eters and their variability were obtained from
previous studies of healthy individuals [10–13].
Protein binding data were obtained from the
product labelling, and the fraction unbound (fu)
was derived by subtracting the% protein binding
from 100%.
Crystal Ball 2000 software (Decisioneering, Inc.,
Denver, CO, USA) was used to create pharmaco-
dynamic models for each bacterium ⁄ b-lactam
combination, based on published pharmacokinetic
data for healthy individuals andMIC distributions
from the 2002 ISS database. Free %T > MIC was
calculated according to the equation:
Free Css=MIC ¼ Cssfu=MIC
where the concentration at steady state (Css,
mg ⁄L) is represented by a log-normal distribu-
tion, the fraction of unbound drug (fu,%) is rep-
resented by a uniform distribution, and the MIC
(mg ⁄L) is represented by a discrete distribution.
The 2002 ISS database comprised susceptibility
data for 2408 pulmonary isolates of Gram-negat-
ive bacteria, including Enterobacteriaceae (n =
1430), P. aeruginosa (n = 799) and A. baumannii
(n = 179). Table 1 lists the MIC50 ⁄ 90 values for
these three bacterial groups of each b-lactam
tested.
Table 2 depicts the results of pharmacodynamic
simulations against the three bacterial groups. The
probability of achieving a Css ⁄MIC ratio of ‡ 1 for
Enterobacteriaceae was ‡ 80% for cefepime, aztre-
onam, ceftazidime and piperacillin–tazobactam.
Table 1. Antibiotic susceptibility of pulmonary isolates of
Gram-negative bacteria from the 2002 Intensive Care Unit
Surveillance System (ISS) database
Antibiotic









Piperacillin–tazobactam 4 ⁄ 64 (84) 4 ⁄ 128 (89) 32 ⁄ 128 (48)
Piperacillin 4 ⁄ 128 (60) 4 ⁄ 128 (84) 128 ⁄ 128 (34)
Ceftazidime 1 ⁄ 32 (85) 2 ⁄ 32 (81) 16 ⁄ 32 (48)
Cefepime 0.06 ⁄ 4 (94) 4 ⁄ 32 (75) 16 ⁄ 64 (39)
Aztreonam 1 ⁄ 32 (85) 4 ⁄ 32 (67) 32 ⁄ 64 (17)
Table 2. Pharmacodynamics of continuous infusion
b-lactams against pulmonary isolates of Enterobacteria-
ceae, Pseudomonas aeruginosa and Acinetobacter baumannii
from the 2002 Intensive Care Unit Surveillance System
(ISS) database
Probabilities (%) that the free Css ⁄MIC ratio will







‡ 1 ‡ 2 ‡ 4 ‡ 1 ‡ 2 ‡ 4 ‡ 1 ‡ 2 ‡ 4
Aztreonam 6 g 88 85 82 78 63 42 36 14 5
Cefepime 3 g 94 91 88 72 51 28 37 28 16
Cefepime 4 g 95 93 90 82 65 43 46 35 25
Ceftazidime 2 g 86 85 83 80 72 53 46 33 14
Ceftazidime 3 g 86 84 83 83 76 63 49 41 24
Piperacillin–tazobactam 6.75 g 82 64 7 79 72 54 40 28 3
Piperacillin–tazobactam 13.5 g 86 84 76 80 73 57 48 42 33
Piperacillin 6 g 58 42 5 63 42 4 20 7 1
Piperacillin 12 g 67 60 50 78 67 52 34 22 8
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Neither piperacillin regimen was ‡ 80% likely to
achieve a Css ⁄MIC ratio of ‡ 1. When the Css ⁄MIC
ratio was raised to ‡ 2, the piperacillin regimens
remained at < 80%, and piperacillin–tazobactam
6.75 g was the only additional antibiotic regimen
with a probability of < 80%. Furthermore, as the
Css ⁄MIC ratio was increased to ‡ 4, piperacillin
6 g, piperacillin 12 g, piperacillin–tazobactam
6.75 g and piperacillin–tazobactam 13.5 g all had
a probability of < 80%. Against P. aeruginosa, only
ceftazidime, cefepime 4 g and piperacillin–tazo-
bactam 13.5 g achieved probabilities of ‡ 80% at a
Css ⁄MIC ratio of ‡ 1. None of the tested b-lactams
achieved probabilities of ‡ 80% at a Css ⁄MIC ratio
of ‡ 1 against A. baumannii.
The rationale behind therapy with continuous
infusion b-lactams has been well-described, and
previous studies have documented equivalent or
improved pharmacodynamics compared with
traditional intermittent administration [11,14,15].
The present study is the ﬁrst comparative evalu-
ation of continuous infusion b-lactam regimens,
and offers valuable information regarding the
predicted efﬁcacy of b-lactams in the ICU setting.
While these studies suggest that the administra-
tion of b-lactams by continuous infusion im-
proves the pharmacodynamics, it is less certain
whether continuous infusion improves patient
outcomes. The available evidence comes largely
from ﬁve small prospective clinical trials [16–20].
Grant et al. [16] compared the clinical efﬁcacy of
continuous vs. intermittent infusion of piperacil-
lin–tazobactam. Days to normalisation of fever
were signiﬁcantly lower in the continuous infu-
sion group (1.2 ± 0.8 days vs. 2.4 ± 1.5 days;
p 0.012). Although the difference was not statis-
tically signiﬁcant, continuous infusion piperacil-
lin–tazobactam outperformed intermittent
infusion piperacillin–tazobactam in clinical efﬁc-
acy (94% vs. 82%; p 0.081) and microbiological
success (89% vs. 73%; p 0.092). In addition, two
small randomised clinical trials have compared
patient outcomes between continuous infusion
and intermittent infusion regimens in neutropenic
patients, and both demonstrated that outcomes
were equal or better with continuous infusion
regimens [17,18]. Other studies have demonstra-
ted similar clinical outcomes among immuno-
competent patients treated with continuous
infusion as opposed to intermittent infusion
b-lactams [19,20].
Presently, there is insufﬁcient evidence to
warrant the replacement of intermittent infusion
by continuous infusion b-lactams as the new
standard for all patient populations. Undoubt-
edly, continuous infusions can be used to max-
imise b-lactam pharmacodynamics; however, it is
still unclear whether continuous infusions will
improve patient outcomes, reduce antibiotic
resistance, minimise toxicities related to peak
concentrations, or decrease healthcare costs.
Overall, the pharmacodynamic simulations in
the present study, based on pharmacokinetic data
from healthy individuals and national microbio-
logical data, suggest that continuous infusion
regimens of cefepime, aztreonam, ceftazidime
and piperacillin–tazobactam 13.5 g have the great-
est likelihood of achieving pharmacodynamic
targets against isolates of Enterobacteriaceae in
the ICU. b-Lactams seemed unlikely to achieve
pharmacodynamic targets against P. aeruginosa or
A. baumannii when administered as monotherapy.
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